STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.
STAT3 is important for transcriptional regulation in human acute myeloid leukemia (AML). STAT3 has thousands of potential DNA binding sites but usually shows cell type specific binding preferences to a limited number of these. Furthermore, AML is a very heterogeneous disease, and studies of the prognostic impact of STAT3 in human AML have also given conflicting results. A more detailed characterization of STAT3 functions and the expression of various isoforms in human AML will therefore be required before it is possible to design clinical studies of STAT3 inhibitors in this disease, and it will be especially important to investigate whether the functions of STAT3 differ between patients. Several other malignancies also show extensive biological heterogeneity, and the present discussion and the suggested scientific approaches may thus be relevant for other cancer patients.
Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Øystein
Ø
Bruserud
Ina
I
Nepstad
Michelle
M
Hauge
Kimberley Joanne
KJ
Hatfield
Håkon
H
Reikvam
D000818:Animals; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D011379:Prognosis; D050796:STAT3 Transcription Factor / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
D050796:STAT3 Transcription Factor
STAT3; acute myeloid leukemia; clinical studies; mitochondria; phosphorylation; prognosis; therapy; transcription